Patent SG-11201804683R-A (SG)
Title: Clinical correlates of immunotherapy efficacy
Inventor: CONNOLLY JOHN
IPC: G01N33/574
Filed: 2016-09-09
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -' Organization International Bureau ires.. 00) (43) International Publication Date ..... ..sr ,„,„. 8 June 2017 (08.06.2017) W I P0 1 PCT (10) WO International 111111111111311111111111111111111111111111111111111111111111111111111111111111111111111111 2017/095324 Publication Number Al (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C12Q 1/68 (2006.01) A61K 35/17 (2015.01) kind of national protection available): AE, AG, AL, AM, GO1N 33/574 (2006.01) A61P 35/00 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, (21) International Application Number: DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/SG2016/050441 HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (22) International Filing Date: KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, 9 September 2016 (09.09.2016) MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (25) Filing Language: English SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, (26) Publication Language: English TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: 10201509979S 4 December 2015 (04.12.2015) SG (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (71) Applicants: AGENCY FOR SCIENCE, TECHNO- GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, LOGY AND RESEARCH [SG/SG]; 1 Fusionopolis Way, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, #20-10 Connexis, Singapore 138632 (SG). TESSA TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, THERAPEUTICS PTE. LTD. [SG/SG]; 46 Kim Yam DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, Road, #01-14 The Herencia, Singapore 239351 (SG). LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SINGAPORE HEALTH SERVICES PTE. LTD. SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, [SG/SG]; 31 Third Hospital Avenue, #03-03, Bowyer GW, KM, ML, MR, NE, SN, TD, TG). Block C, Singapore 168753 (SG). Declarations under Rule 4.17: Inventors: CONNOLLY, John; do Institute Molecular (72) of — 4.17(iv)) & Cell Biology, 61 Biopolis Drive, Singapore 138673 of inventorship (Rule (SG). HOPKINS, Richard; do Tessa Therapeutics Pte. Published: Ltd., 46 Kim Yam Road, #01-14 The Herencia, Singapore — with international search report (Art 21(3)) 239351 (SG). TOH, Han Chong; c/o National Cancer Centre, 11 Hospital Drive, Singapore 169610 (SG). (74) Agent: SPRUSON & FERGUSON (ASIA) PTE LTD; P.O. Box 1531, Robinson Road Post Office, Singapore 903031 (SG). (54) Title: CLINICAL CORRELATES OF IMMUNOTHERAPY EFFICACY > 1 ‘% :‘ I I I 1 1 . ‘AttNa Pre Chemo Infusion 1 Infusion 2 Infusion 3 Infusion 6 T-1 T5 TO T1 T2 32 Weeks 0 Weeks 2 Weeks 4 Weeks E 11 W 0 .4t TD_ ., r • E (13 m — 71° co () 7 ci ei M in Figure 1 Cr1 0 ----. (57) : A method for predicting whether a patient will be a long-term survivor on treatment of a disease by adoptive cell I N transfer (ACT), is disclosed comprising: (i) analysing a blood-derived sample obtained from the patient for one or more prognostic 1-1 c:::, markers of long-term survival on treatment of a disease by ACT, and; (ii) based on the analysis of step (i), predicting whether the pa - ei tient will be a long-term survivor on treatment of the disease by ACT, wherein the disease is preferably a disease caused or exacer - 0 bated by infection with Epstein-Barr virus (EBV), such as EBV-positive nasopharyngeal carcinoma (NPC). Also disclosed are meth- ods for treating a patient by ACT, methods for selecting a patient for treatment by ACT, and methods for selecting a patient for treat- ment of a disease by ACT, preferably EBV-positive NPC.